MOG (35-55): Benchmark Peptide for Experimental Autoimmune Encephalomyelitis Models

Executive Summary: MOG (35-55) is a synthetic peptide corresponding to amino acids 35–55 of human myelin oligodendrocyte glycoprotein, widely used to induce EAE in murine models of multiple sclerosis. This peptide elicits robust T and B cell immune responses, resulting in reproducible, relapsing-remitting neurological symptoms and demyelination in susceptible strains (Xu et al., 2025). Solubility is high in water (≥32.25 mg/mL) and DMSO (≥86 mg/mL), but it is insoluble in ethanol; optimal stock solutions are prepared in sterile water at 0.50 mg/mL. Subcutaneous administration (50–150 μg/mouse) with CFA reliably induces MS-like pathology and weight loss in mice, enabling rigorous preclinical studies of neuroinflammation and therapeutic interventions (APExBIO). In vitro, MOG (35-55) activates NADPH oxidase and MMP-9, reflecting its role in oxidative stress and matrix remodeling pathways.

Biological Rationale

MOG (35-55) is derived from the extracellular domain of myelin oligodendrocyte glycoprotein, an immunoglobulin superfamily protein expressed on oligodendrocyte surfaces in the CNS [APExBIO product page]. This peptide is the minimal epitope inducing encephalitogenic T cell responses in C57BL/6 and other mouse strains. Its use enables the modeling of relapsing-remitting and progressive forms of multiple sclerosis through induction of EAE, characterized by perivascular inflammatory infiltrates and demyelination. The model provides a platform for dissecting the immunopathology underlying human MS and evaluating candidate therapies targeting neuroinflammation, immune tolerance, and remyelination [contrast: expands on molecular action].

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as a potent autoantigen. Upon administration with complete Freund's adjuvant, it is processed by antigen-presenting cells and presented on MHC class II molecules. This presentation activates CD4+ T cells specific to the MOG (35-55) epitope, leading to clonal expansion and cytokine release. The resulting cascade recruits B cells, promotes autoantibody formation, and drives infiltration of mononuclear cells into CNS white matter, resulting in demyelination (Xu et al., 2025). In vitro, the peptide increases NADPH oxidase and MMP-9 activity, linking it to oxidative stress and extracellular matrix remodeling.

Evidence & Benchmarks

• MOG (35-55) (50–150 μg/mouse, subcutaneous, with CFA) consistently induces EAE in C57BL/6 and HLA-DR2-transgenic mice, manifesting as ascending paralysis and CNS demyelination (Xu et al., 2025).
• Peptide is highly soluble in water (≥32.25 mg/mL) and DMSO (≥86 mg/mL), but insoluble in ethanol, facilitating preparation of reproducible dosing solutions (APExBIO).
• In vitro exposure to MOG (35-55) results in dose-dependent increases in NADPH oxidase and MMP-9 activity, highlighting its role in oxidative stress and matrix remodeling (see advanced applications).
• Stock solutions should be prepared in sterile water at 0.50 mg/mL, stored at -20°C, and used promptly to avoid degradation (APExBIO).
• PARP7 inhibition in the EAE model (using MOG (35-55) induction) relieves neurological symptoms by stabilizing STAT1/STAT2 and enhancing type I interferon signaling (Xu et al., 2025).

Applications, Limits & Misconceptions

MOG (35-55) is essential for preclinical evaluation of MS therapeutics, immunomodulators, and interventions targeting neuroinflammatory cascades. It serves for the validation of immunological hypotheses regarding T and B cell roles in CNS autoimmunity [contrast: streamlines protocol application]. However, its utility is limited to animal models and does not recapitulate all aspects of human MS. The peptide is ineffective in mouse strains lacking the relevant MHC class II alleles, and results are influenced by adjuvant type and dosing regimen.

Common Pitfalls or Misconceptions

• Not all mouse strains respond: Strains lacking compatible MHC class II molecules (e.g., BALB/c) do not develop EAE with MOG (35-55).
• Solubility errors: Ethanol is unsuitable; always use water or DMSO for stock preparation.
• Improper storage: Degradation occurs if not kept desiccated at -20°C; avoid repeated freeze-thaw cycles.
• Assuming full recapitulation of human MS: The EAE model mimics key features but does not encompass all MS immunopathology.
• Overlooking batch variability: Use validated sources like APExBIO for reproducibility.

Workflow Integration & Parameters

MOG (35-55) is typically administered subcutaneously at 50–150 μg/mouse, emulsified in complete Freund's adjuvant (CFA). Pertussis toxin is often co-administered to enhance blood-brain barrier permeability. Stock solutions should be prepared in sterile water (0.50 mg/mL), with mild warming and ultrasonic bath treatment to ensure dissolution. Use within one week of preparation; store at -20°C, desiccated. In vitro assays utilize concentrations up to 32.25 mg/mL in water or 86 mg/mL in DMSO, depending on experimental requirements. For detailed molecular insights and troubleshooting, see this recent mechanistic review, which this article extends by providing updated solubility and workflow parameters.

Conclusion & Outlook

MOG (35-55) remains the gold standard for inducing EAE and modeling neuroinflammatory mechanisms in multiple sclerosis research. Its precise epitope specificity, high solubility, and reproducibility have enabled fundamental discoveries in autoimmune disease mechanisms and therapeutic screening. Ongoing advances—including the use of PARP7 inhibitors—underscore the evolving translational value of this model system (Xu et al., 2025). For best results, source validated peptide such as the APExBIO A8306 kit and adhere to optimized workflow guidelines.